{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:32:33Z","timestamp":1780515153694,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rapidly progressive interstitial lung disease is typically associated with clinically amyopathic dermatomyositis and the anti-melanoma differentiation associated gene 5 antibody, a condition with high mortality and resistance to classic immunosuppression. Recent reports have described the efficacy of the Janus kinase inhibitor tofacitinib in the treatment of rapidly progressive interstitial lung disease in anti-melanoma differentiation associated gene 5 antibody-positive clinically amyopathic dermatomyositis. It is uncertain, however, whether tofacitinib alters the course of rapidly progressive interstitial lung disease in other variants of dermatomyositis that are unrelated to the anti-melanoma differentiation associated gene 5 antibody and whether the early addition of the anti-fibrotic tyrosine kinase inhibitor nintedanib interferes with the development of fibrosis. To answer these questions, we present and discuss the case of an elderly woman who presented with a flare of dermatomyositis <jats:italic>sine<\/jats:italic> myositis. Based upon the detection of anti-Jo-1 antibodies and the absence of anti-melanoma differentiation associated gene 5 antibodies, anti-synthetase syndrome was diagnosed. While the cutaneous manifestations quickly resolved with prednisone, azathioprine and tacrolimus, the respiratory function paradoxically and rapidly deteriorated, and invoked the use of tofacitinib. Markedly raised ferritin levels and a severe numerical deficiency of circulating natural killer cells paralleled the acute lung inflammation, which was reflected by <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose hypermetabolism on positron emission tomography\/CT. Tofacitinib lead to a prompt clinical recovery, with a reduction in oxygen requirement, correction of hyperferritinemia, reversal of the natural killer cell deficiency, and a decrease in <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose uptake in the affected lung segments. Subsequently, nintedanib was added at a point in time when inflammation subsided. Apart from cytomegalovirus reactivation no adverse events occurred. In conclusion, tofacitinib reversed the pronounced inflammatory component of anti-Jo-1 antibody-positive, anti-melanoma differentiation associated gene 5 antibody-negative rapidly progressive interstitial lung disease, confirming that Janus kinase signaling pathways are critically involved in the pathogenesis of rapidly progressive interstitial lung disease, apparently independently of the targeted autoantigen. Although some improvement in pulmonary function was observed, it seems premature to conclusively judge on reversibility or prevention of pulmonary fibrosis by pairing both kinase inhibitors for which an extended follow-up and ideally, prospective and controlled studies are needed.<\/jats:p>","DOI":"10.3389\/fphar.2020.585761","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:52:59Z","timestamp":1610308379000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Walter","family":"Conca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab","family":"Weheba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohei-Eldin","family":"Abouzied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Abdelsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Aleyouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eid","family":"Al\u2010Mutairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol. Lett."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00262-008-0600-8","article-title":"Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins","volume":"58","author":"Dodds","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ebiom.2016.02.025","article-title":"Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency","volume":"6","author":"Ebbo","year":"2016","journal-title":"EBioMedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1515\/BC.1999.079","article-title":"Histidyl-tRNA synthetase","volume":"380","author":"Freist","year":"1999","journal-title":"Biol. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.4049\/jimmunol.1501902","article-title":"Involvement of NK cells and NKp30 pathway in antisynthetase syndrome","volume":"197","author":"Hervier","year":"2016","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3389\/fimmu.2019.01263","article-title":"NK cells in the human lungs","volume":"10","author":"Hervier","year":"2019","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis","author":"Kato","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2169\/internalmedicine.49.2889","article-title":"Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies","volume":"49","author":"Koreeda","year":"2010","journal-title":"Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37616","DOI":"10.1074\/jbc.M607266200","article-title":"Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain","volume":"281","author":"Li","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5312\/wjo.v5.i4.504","article-title":"Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis","volume":"5","author":"Lundquist","year":"2014","journal-title":"World J. Orthoped."},{"key":"B20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/82_2010_20","article-title":"Role of chemokines in the biology of natural killer cells","volume":"341","author":"Maghazachi","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13294","DOI":"10.1371\/journal.pone.0013294","article-title":"Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo","volume":"5","author":"Morteau","year":"2010","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cyto.2012.08.032","article-title":"Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"61","author":"Oishi","year":"2013","journal-title":"Cytokine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaci.2013.07.020","article-title":"Natural killer cell deficiency","volume":"132","author":"Orange","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2169\/internalmedicine.8335-16","article-title":"The serum ferritin level is associated with the treatment responsivity for rapidly progressive interstitial lung disease with amyopathic dermatomyositis, irrespective of the anti-MDA5 antibody level","volume":"57","author":"Osawa","year":"2018","journal-title":"Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fimmu.2014.00342","article-title":"Pattern recognition and signaling mechanisms of RIG-I and MDA5","volume":"23","author":"Reikine","year":"2014","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/01.bor.0000434676.70268.66","article-title":"Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies","volume":"25","author":"Rothwell","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1005973","DOI":"10.1371\/journal.ppat.1005973","article-title":"IL-1\u03b2\/IL-6\/CRP and IL-18\/ferritin: distinct inflammatory programs in infections","volume":"12","author":"Slaats","year":"2016","journal-title":"PLoS Pathog."},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1600-0897.2007.00574.x","article-title":"Prednisolone suppresses NK cell cytotoxicity in vitro in women with a history of infertility and elevated NK cell cytotoxicity","volume":"59","author":"Thum","year":"2008","journal-title":"Am. J. Reprod. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/rheumatology\/key341","article-title":"CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - a report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J. Autoimmun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1038\/s41467-019-11878-3","article-title":"NK cells are activated and primed for skin-homing during acute dengue virus infection in humans","volume":"10","author":"Zimmer","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.585761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:53:03Z","timestamp":1610308383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.585761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":37,"alternative-id":["10.3389\/fphar.2020.585761"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.585761","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"article-number":"585761"}}